ScholarLens Back to search
2018•CirculationRequires access

Abstract 14858: CRD-733, a Novel Phosphodiesterase 9 Inhibitor, Reverses Pressure Overload-Induced Cardiac Hypertrophy in Mice

Daniel A. Richards, Mark Aronovitz, Richard H. Karas, Daniel M. Bloomfield, Michael E. Mendelsohn, Robert M. Blanton

Open publisher page 0 citations

Abstract

Introduction: Myocardial cyclic GMP (cGMP) elevation and activation of cGMP-dependent protein kinase (PKG) have been shown to attenuate pathological cardiac hypertrophy and remodeling. Expression o...

About this research paper

What this paper is about

Introduction: Myocardial cyclic GMP (cGMP) elevation and activation of cGMP-dependent protein kinase (PKG) have been shown to attenuate pathological cardiac hypertrophy and remodeling. Expression o...

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction: Myocardial cyclic GMP (cGMP) elevation and activation of cGMP-dependent protein kinase (PKG) have been shown to attenuate pathological cardiac hypertrophy and remodeling. Expression o...

Key concepts: Medicine, Pressure overload, Cardiac hypertrophy, Phosphodiesterase inhibitor, Muscle hypertrophy, Internal medicine, Cardiology, Phosphodiesterase

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Abstract 14858: CRD-733, a Novel Phosphodiesterase 9 Inhibitor, Reverses Pressure Overload-Induced Cardiac Hypertrophy in Mice — Research Paper | ScholarLens